CART-BCMA

BIOLOGICAL3 trials

Sponsors

University of Pennsylvania, Shanghai Simnova Biotechnology Co.,Ltd., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

End Stage Renal Failure on DialysisKidney FailureKidney TransplantMultiple Myeloma

Phase 1

CART-BCMA Cells for Multiple Myeloma

CompletedNCT02546167

University of PennsylvaniaMultiple Myeloma

Start: 2015-09-03End: 2020-07-27Updated: 2025-06-25

Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma

Active, not recruitingNCT05346198

Shanghai Simnova Biotechnology Co.,Ltd.Multiple Myeloma

Start: 2021-03-12End: 2024-12-31Target: 15Updated: 2024-02-23

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

RecruitingNCT06056102

National Institute of Allergy and Infectious Diseases (NIAID)End Stage Renal Failure on Dialysis, Kidney Failure, Kidney Transplant

Start: 2024-05-09End: 2042-12-15Target: 20Updated: 2026-05-22

Related Papers

Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies

Cell Reports Medicine2023-12-0120 citations

Phase I Clinical Study of Humanized BCMA-Single-Domain Antibodies-Targeting CAR T (BCMA-CART) in Patients with Relapsed/Refractory Multiple Myeloma

Blood2023-11-022 citations

Perfecting CAR Engraftment to a Tee (Cell) through Characterization of Single Cell Transcriptome Product and Understanding Neurotoxicity

Blood2021-11-051 citations

Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials

Frontiers in Immunology2021-10-2948 citations

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

2019-03-21585 citations

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

Future Oncology2019-02-2829 citations

Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma

Blood2018-11-2936 citations

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma

Journal of Hematology & Oncology2018-10-2261 citations

Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma

Oncotarget2018-05-2570 citations

Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide

Blood2016-12-0246 citations